Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CLL-1 CAR NK cells
- Development stage
- Unknown
- Lead developer
- Qihan Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CLL-1 CAR NK cells are natural killer (NK) cells that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting C-type lectin-like molecule 1 (CLL1), an antigen highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells but not on healthy hematopoietic stem cells. The addition of the anti-CLL-1 CAR enables these NK cells to specifically recognize and kill AML cancerous cells with improved specificity. Compared to traditional T cell-based therapies, such as CAR-T, anti-CLL-1 CAR NK cell therapy offers advantages including a lower risk of cytokine release syndrome, neurotoxicity, and graft-versus-host disease. These therapies are being developed as "off-the-shelf" allogeneic products for the treatment of AML[3][4][1].
- Other names
- CLL1 CAR-NK cellsCLL-1 CAR-NK cellsCLL 1 CAR-NK cellsCLL1-targeted CAR-NK cellsCLL-1-targeted CAR-NK cellsCLL 1-targeted CAR-NK cells
02
Targets
CLEC12A
Beyond the preview
Go deeper on anti-CLL-1 CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CLL-1 CAR NK cells.